OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M |
| Total Depreciation and Amortization | 491.00K | 563.00K | 340.00K | 326.00K | 335.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.37M | 28.75M | 7.60M | -595.00K | 3.95M |
| Change in Net Operating Assets | -1.04M | -1.16M | -2.00K | -1.18M | 1.02M |
| Cash from Operations | -5.86M | -5.35M | -5.55M | -5.98M | -3.83M |
| Capital Expenditure | -307.00K | -214.00K | -87.00K | -191.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | 4.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -307.00K | -210.00K | -87.00K | -191.00K | -24.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -98.00K | -82.00K | -86.00K | -33.00K | -- |
| Issuance of Common Stock | 29.14M | 11.99M | 18.00K | 15.81M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 0.00 | 0.00 | -5.39M | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -487.00K | -1.07M | -187.00K | -538.00K | -- |
| Cash from Financing | 28.56M | 10.84M | -255.00K | 9.85M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.39M | 5.27M | -5.89M | 3.68M | -3.85M |